NASDAQ : PVLA

Palvella Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 151.58 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.18B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.

Details

NamePalvella Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees29
Founded2015
CeoWesley Kaupinen
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS6979471090
Cusip697947109
Cik0001583648
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Wesley H. KaupinenFounder, President, Chief Executive Officer and Director
Matthew E. KorenbergChief Financial Officer, Corporate Secretary and Treasurer
Kathleen GoinChief Operating Officer
Dr. Jeffrey Martini Ph.D.Chief Scientific Officer
Marcy B. NanusVice President of Investor Relations and Corporate Affairs
Colleen Kelly J.D.Vice President and Head of Legal
Bohan WeiVice President of Corporate Development and New Product Planning
Kent TaylorSenior Vice President of Sales
Sarah FosterSenior Vice President of Human Resources
Emily CookSenior Vice President of Clinical Operations

Contact

Address353 W. Lancaster Avenue, Suite 200, Wayne, Pennsylvania 19087, United States
Phone484 253 1461
Websitehttps://palvellatx.com